These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30710172)

  • 1. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy.
    Zhou L; Chong V; Lai K; Huang C; Xu F; Gong Y; Youlidaxi M; Li T; Lu L; Jin C
    Lasers Med Sci; 2019 Sep; 34(7):1345-1351. PubMed ID: 30710172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy.
    Kim JY; Park HS; Kim SY
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2129-35. PubMed ID: 25717024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.
    Arsan A; Kanar HS; Sonmez A
    Eye (Lond); 2018 Apr; 32(4):726-733. PubMed ID: 29303148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy.
    Uzlu D; Erdöl H; Kola M; Özbay AD
    Lasers Med Sci; 2021 Jul; 36(5):981-988. PubMed ID: 32812130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two protocols of subthreshold micropulse yellow laser treatment for non-resolving central serous chorioretinopathy.
    Beniwal A; Shaikh N; Chawla R; Azad SV; Kumar V; Vohra R
    Indian J Ophthalmol; 2022 Sep; 70(9):3341-3345. PubMed ID: 36018117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years.
    Kim YJ; Kim SY; Ha S; Moon D; Seong S; Kwon OW; Park HS
    Eye (Lond); 2019 May; 33(5):819-825. PubMed ID: 30610228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 577 nm subthreshold micropulse laser treatment for acute central serous chorioretinopathy: a comparative study.
    Long H; Liu M; Hu Q; Li X
    BMC Ophthalmol; 2022 Mar; 22(1):105. PubMed ID: 35248003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.
    Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M
    Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Grzybowski A
    Graefes Arch Clin Exp Ophthalmol; 2017 Dec; 255(12):2299-2306. PubMed ID: 28831603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy.
    Malik KJ; Sampat KM; Mansouri A; Steiner JN; Glaser BM
    Retina; 2015 Mar; 35(3):532-6. PubMed ID: 25127050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Fluence Photodynamic Therapy versus Subthreshold Micropulse Yellow Wavelength Laser in the Treatment of Chronic Central Serous Chorioretinopathy.
    Özmert E; Demirel S; Yanık Ö; Batıoğlu F
    J Ophthalmol; 2016; 2016():3513794. PubMed ID: 27597894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy.
    Oh J; Yoon CK; Kim BH; Yu HG
    Korean J Ophthalmol; 2021 Feb; 35(1):51-63. PubMed ID: 33307626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy.
    An SH; Kwon YH
    Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1489-1496. PubMed ID: 26553195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective retina therapy (SRT) in patients with therapy refractory persistent acute central serous chorioretinopathy (CSC): 3 months functional and morphological results.
    Büttner M; Luger B; Abou Moulig W; Junker B; Framme C; Jacobsen C; Knoll K; Pielen A;
    Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1401-1410. PubMed ID: 33205239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthreshold Micropulse Laser vs. Conventional Laser for Central Serous Chorioretinopathy: A Randomized Controlled Clinical Trial.
    Zhou L; Lai K; Jin L; Huang C; Xu F; Gong Y; Li L; Zhu Z; Lu L; Jin C
    Front Med (Lausanne); 2021; 8():682264. PubMed ID: 34336888
    [No Abstract]   [Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.
    Park YG; Kang S; Kim M; Yoo N; Roh YJ
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1375-1383. PubMed ID: 28421342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.